Cai Jing Wang·2025-12-22 02:36Core Viewpoint - The announcement highlights a licensing and collaboration agreement between the company and AstraZeneca regarding the pan-KRAS inhibitor JAB-23E73, which is expected to enhance the company's global cooperation network and maximize the scientific and commercial value of its technology platform [1]. Group 1: Agreement Details - The company will receive an upfront payment of $100 million from AstraZeneca and is eligible for additional milestone payments totaling up to $1.915 billion upon achieving various development, regulatory, and commercial milestones [1]. - AstraZeneca will obtain exclusive rights to research, develop, register, manufacture, and commercialize JAB-23E73 globally, excluding China (including Hong Kong, Macau, and Taiwan) [1]. - The company is required to provide necessary technology transfer, data, and reasonable assistance to AstraZeneca [1]. Group 2: Responsibilities and Costs - AstraZeneca will be responsible for the main activities and costs related to development, regulatory affairs, and commercialization in its regions, while activities and costs in China will be jointly borne by both parties [1]. - The board believes that this agreement aligns with the overall best interests of the company and its shareholders [1].